Loading…
Impact of pharmacogenetics on aspirin resistance: a systematic review
Abstract Background Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have tr...
Saved in:
Published in: | Arquivos de neuro-psiquiatria 2023-01, Vol.81 (1), p.062-073 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Abstract
Background
Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have treatment failure due to genetic variants that modify the metabolism of the drug causing aspirin resistance (AR).
Objectives
To realize a systematic literature review to determine the impact of genetic variants on AR.
Methods
Articles published in the MEDLINE/PubMed, Cochrane, Scopus, LILACS, and SCIELO databases were systematically screened. A total of 290 articles were identified and 269 articles were excluded because they did not comply with the previously established inclusion criteria. A total of 20 case-control studies and 1 cohort was included.
Results
The genetic variants rs1126643 (
ITGA2
), rs3842787 (
PTGS1
), rs20417 (
PTGS2
), and rs5918 (
ITGB3
) were the most studied. As for relevance, of the 64 genetic variants evaluated by the articles, 14 had statistical significance (
p
|
---|---|
ISSN: | 0004-282X 1678-4227 1678-4227 |
DOI: | 10.1055/s-0042-1758445 |